IN2014MN02598A - - Google Patents

Info

Publication number
IN2014MN02598A
IN2014MN02598A IN2598MUN2014A IN2014MN02598A IN 2014MN02598 A IN2014MN02598 A IN 2014MN02598A IN 2598MUN2014 A IN2598MUN2014 A IN 2598MUN2014A IN 2014MN02598 A IN2014MN02598 A IN 2014MN02598A
Authority
IN
India
Prior art keywords
compounds
disclosed
formula
methods
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Kyla Bjornson
Eda Canales
Jeromy J Cottell
Kapil Kumar Karki
Ashley Anne Katana
Darryl Kato
Tetsuya Kobayashi
John O Link
Ruben Martinez
Barton W Phillips
Hyung Jung Pyun
Michael Sangi
Adam James Schrier
Dustin Siegel
James G Taylor
Chinh Viet Tran
Martin Teresa Alejandra Trejo
Randall W Vivian
Zheng Yu Yang
Jeff Zablocki
Sheila Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48803614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN02598(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of IN2014MN02598A publication Critical patent/IN2014MN02598A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2598MUN2014 2012-07-03 2013-07-02 IN2014MN02598A (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261667806P 2012-07-03 2012-07-03
US201361798524P 2013-03-15 2013-03-15
PCT/US2013/049119 WO2014008285A1 (en) 2012-07-03 2013-07-02 Inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
IN2014MN02598A true IN2014MN02598A (ar) 2015-07-24

Family

ID=48803614

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2598MUN2014 IN2014MN02598A (ar) 2012-07-03 2013-07-02

Country Status (41)

Country Link
US (7) US9296782B2 (ar)
EP (4) EP3159345B1 (ar)
JP (4) JP6025977B2 (ar)
KR (3) KR101610575B1 (ar)
CN (2) CN104540832B (ar)
AP (1) AP3903A (ar)
AR (1) AR091661A1 (ar)
AU (6) AU2013286729B2 (ar)
BR (2) BR112014033080B1 (ar)
CA (1) CA2877005C (ar)
CL (1) CL2014003634A1 (ar)
CO (1) CO7160104A2 (ar)
CR (1) CR20150045A (ar)
CY (2) CY1118379T1 (ar)
DK (2) DK3159345T3 (ar)
EA (2) EA033961B1 (ar)
EC (1) ECSP15002066A (ar)
ES (3) ES2605383T3 (ar)
HK (2) HK1209416A1 (ar)
HR (2) HRP20161379T1 (ar)
HU (2) HUE042345T2 (ar)
IL (4) IL236500B (ar)
IN (1) IN2014MN02598A (ar)
LT (2) LT3159345T (ar)
MD (2) MD20180040A2 (ar)
ME (2) ME02547B (ar)
MX (2) MX360597B (ar)
MY (1) MY173342A (ar)
NZ (2) NZ739248A (ar)
PE (1) PE20150204A1 (ar)
PH (3) PH12014502862A1 (ar)
PL (2) PL2870160T3 (ar)
PT (2) PT3159345T (ar)
RS (2) RS58409B1 (ar)
SG (3) SG11201408739VA (ar)
SI (2) SI3159345T1 (ar)
SM (1) SMT201600470B (ar)
TW (1) TWI602822B (ar)
UA (1) UA119315C2 (ar)
UY (1) UY34888A (ar)
WO (1) WO2014008285A1 (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
LT2909205T (lt) 2012-10-19 2016-12-27 Bristol-Myers Squibb Company 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
EA029088B1 (ru) * 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
EP3087086B1 (en) 2013-12-23 2018-11-07 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
PT3087085T (pt) * 2013-12-23 2019-06-04 Gilead Sciences Inc Síntese de um tripéptido macrocíclico inibidor de ns3 de hcv
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
US20180050976A1 (en) * 2015-02-16 2018-02-22 Central Glass Company, Limited Practical Processes for Producing Fluorinated alpha-Ketocarboxylic Esters and Analogues Thereof
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
BR112018073858A2 (pt) 2016-05-27 2019-02-26 Gilead Sciences, Inc. métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
JOP20190052A1 (ar) 2016-09-22 2019-03-21 Astrazeneca Ab 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز
AU2018215337A1 (en) * 2017-02-01 2019-08-22 Abbvie Inc. Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and(±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030091946A (ko) 2000-12-12 2003-12-03 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US6869964B2 (en) 2002-05-20 2005-03-22 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis C virus inhibitors
EP1505945B1 (en) 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
EP1506172B1 (en) 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EP1615613B1 (en) 2003-04-18 2009-11-04 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
KR101115294B1 (ko) 2003-05-21 2012-04-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 억제제 화합물
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ATE516293T1 (de) 2004-07-16 2011-07-15 Gilead Sciences Inc Antivirale verbindungen
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
EP1879607B1 (en) 2005-05-02 2014-11-12 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EP2305695A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
JP4705984B2 (ja) * 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
AU2007309488B2 (en) 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008051477A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
KR101615500B1 (ko) 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
CN101568346B (zh) 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
US20090155209A1 (en) 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
CA2691442C (en) 2007-06-29 2014-01-21 Gilead Sciences, Inc. Antiviral compounds
CN101801925A (zh) 2007-06-29 2010-08-11 吉里德科学公司 抗病毒组合物
CA2699891C (en) 2007-07-19 2013-10-22 Nigel Liverton Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
EP2190858A4 (en) 2007-09-24 2013-02-13 Achillion Pharmaceuticals Inc PEPTIDES CONTAINING UREA AS INHIBITORS OF VIRAL REPLICATION
WO2009055467A2 (en) 2007-10-24 2009-04-30 Virobay, Inc. Compounds that inhibit protease cathepsin s and hcv replication
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
JP2011506329A (ja) 2007-12-05 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド キノキサリニル誘導体
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
MX2010006736A (es) 2007-12-21 2010-10-15 Avila Therapeutics Inc Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CN102036966A (zh) 2008-01-24 2011-04-27 益安药业 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
CN101977915B (zh) 2008-02-04 2014-08-13 埃迪尼克斯医药公司 大环丝氨酸蛋白酶抑制剂
AU2009217551B2 (en) 2008-02-25 2014-07-31 Msd Italia S.R.L. Therapeutic compounds
US8431733B2 (en) 2008-03-12 2013-04-30 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
US8372802B2 (en) 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
MX2010011306A (es) 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
CN102159285B (zh) 2008-07-22 2014-05-14 默沙东公司 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物
ES2461841T3 (es) 2008-08-07 2014-05-21 F. Hoffmann-La Roche Ag Proceso para la preparación de un macrociclo
CA2734744A1 (en) 2008-08-20 2010-02-25 Michael Eissenstat Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
NZ602163A (en) 2008-09-16 2013-06-28 Boehringer Ingelheim Int Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hepatitis c viral inhibitor
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AP2011005695A0 (en) 2008-10-15 2011-06-30 Intermune Inc Therapeutic antiviral poptides.
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
US8445430B2 (en) 2008-11-20 2013-05-21 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
DK2358355T3 (da) 2008-11-21 2013-12-16 Boehringer Ingelheim Int Farmaceutisk sammensætning af en potent HCV-inhibitor til oral indgivelse
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2746265A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2011006631A (es) 2008-12-19 2011-09-06 Gilead Sciences Inc Inhibidores de proteasa ns3 del virus hcv.
PL2382198T3 (pl) 2008-12-23 2013-11-29 Janssen Pharmaceuticals Inc Sposoby i półprodukty do otrzymywania makrocyklicznego inhibitora proteazy HCV
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
EP2432318A4 (en) 2009-05-22 2012-11-21 Sequoia Pharmaceuticals Inc NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
AU2010277171B2 (en) 2009-07-31 2013-02-07 Cadila Healthcare Limited Substituted benzamide derivatives as glucokinase (GK) activators
US8637449B2 (en) 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
MX2012003500A (es) 2009-09-28 2012-08-01 Intermune Inc Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c.
US20110082182A1 (en) 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
CN104771364B (zh) 2010-03-10 2018-05-25 艾伯维巴哈马有限公司 固体组合物
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
CN103025736B (zh) 2010-06-07 2016-07-06 Abbvie公司 大环的丙型肝炎丝氨酸蛋白酶抑制剂
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US20120094897A1 (en) 2010-09-15 2012-04-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
JP5857053B2 (ja) 2010-09-21 2016-02-10 エナンタ ファーマシューティカルズ インコーポレイテッド 大環式プロリン由来ｈｃｖセリンプロテアーゼ阻害剤
WO2012040040A1 (en) 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8729014B2 (en) 2010-11-01 2014-05-20 Rfs Pharma, Llc Specific HCV NS3 protease inhibitors
BR112013010372A2 (pt) 2010-12-14 2016-07-05 Merck Sharp & Dohme composto, e, método para preparar um composto
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2726475B1 (en) 2011-05-27 2017-10-25 Bristol-Myers Squibb Company Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
EP2723337A1 (en) 2011-06-23 2014-04-30 Panmed Ltd. Treatment of hepatitis c virus
EP2744331A4 (en) 2011-08-19 2015-01-21 Merck Sharp & Dohme METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN
AU2012332832A1 (en) 2011-10-31 2014-04-17 Msd Italia S.R.L. Compositions useful for the treatment of viral diseases
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
SG11201404042VA (en) 2012-01-12 2014-08-28 Boehringer Ingelheim Int Stabilized pharmaceutical formulations of a potent hcv inhibitor
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c

Also Published As

Publication number Publication date
BR112014033080A2 (pt) 2017-06-27
BR112014033080B1 (pt) 2022-03-29
NZ739248A (en) 2019-05-31
PH12014502862B1 (en) 2015-02-23
AU2017203984A1 (en) 2017-07-06
US9296782B2 (en) 2016-03-29
EP3825312A1 (en) 2021-05-26
ECSP15002066A (es) 2015-11-30
IL261581B (en) 2019-10-31
KR20190124346A (ko) 2019-11-04
US20140017198A1 (en) 2014-01-16
CY1118379T1 (el) 2017-06-28
AU2019222909B2 (en) 2021-03-25
HUE042345T2 (hu) 2019-06-28
PH12016502040A1 (en) 2019-02-27
US10603318B2 (en) 2020-03-31
DK3159345T3 (en) 2019-03-25
DK2870160T3 (en) 2017-01-23
JP2018154651A (ja) 2018-10-04
IL236500B (en) 2018-02-28
MD20140136A2 (ro) 2015-05-31
UA119315C2 (uk) 2019-06-10
RS58409B1 (sr) 2019-04-30
CY1121418T1 (el) 2020-05-29
TWI602822B (zh) 2017-10-21
MX2014015846A (es) 2015-08-14
HK1210151A1 (en) 2016-04-15
AP2014008166A0 (en) 2014-12-31
AU2016200670A1 (en) 2016-02-25
US20190365748A1 (en) 2019-12-05
ME02547B (me) 2017-02-20
IL236500A0 (en) 2015-02-26
PT2870160T (pt) 2016-12-12
CA2877005A1 (en) 2014-01-09
SG11201408739VA (en) 2015-01-29
AU2013286729B2 (en) 2015-11-12
HRP20190578T1 (hr) 2019-05-17
MD4602B1 (ro) 2018-11-30
HRP20161379T1 (hr) 2016-12-02
EA201492214A1 (ru) 2015-10-30
UY34888A (es) 2014-01-31
AR091661A1 (es) 2015-02-18
MX2018013668A (es) 2019-01-28
EP3492464B1 (en) 2020-08-19
KR101610575B1 (ko) 2016-04-07
EA201790661A3 (ru) 2017-10-31
MY173342A (en) 2020-01-17
HK1209416A1 (en) 2016-04-01
SI2870160T1 (sl) 2016-11-30
CO7160104A2 (es) 2015-01-15
PL2870160T3 (pl) 2017-05-31
NZ703064A (en) 2016-12-23
LT3159345T (lt) 2019-03-12
ME03362B (me) 2019-10-20
WO2014008285A1 (en) 2014-01-09
JP2020143107A (ja) 2020-09-10
AU2016200201A1 (en) 2016-02-04
US9655944B2 (en) 2017-05-23
US20190008858A1 (en) 2019-01-10
EP3159345B1 (en) 2019-01-09
PT3159345T (pt) 2019-04-15
ES2827300T3 (es) 2021-05-20
JP6025977B2 (ja) 2016-11-16
EA027390B1 (ru) 2017-07-31
EA201790661A2 (ru) 2017-08-31
AU2019222909A1 (en) 2019-09-19
RS55494B1 (sr) 2017-04-28
EP3492464A1 (en) 2019-06-05
KR102040023B1 (ko) 2019-11-05
BR122021012378B1 (pt) 2022-05-10
US20170290827A1 (en) 2017-10-12
CN106117309A (zh) 2016-11-16
AU2013286729A1 (en) 2015-01-22
PH12014502862A1 (en) 2015-02-23
JP2015523365A (ja) 2015-08-13
SMT201600470B (it) 2017-03-08
AU2017203984B2 (en) 2019-06-06
HUE032404T2 (en) 2017-09-28
CN104540832A (zh) 2015-04-22
AU2021204238A1 (en) 2021-07-22
US20160361375A1 (en) 2016-12-15
IL261581A (en) 2018-10-31
IL269662A (en) 2019-11-28
KR20160040743A (ko) 2016-04-14
CN106117309B (zh) 2019-08-30
IL252446A0 (en) 2017-07-31
SG10201702950TA (en) 2017-06-29
AP3903A (en) 2016-11-17
EP2870160B1 (en) 2016-09-28
PE20150204A1 (es) 2015-02-12
US20150175655A1 (en) 2015-06-25
CN104540832B (zh) 2016-08-24
JP2016041743A (ja) 2016-03-31
SI3159345T1 (sl) 2019-03-29
SG10201912269YA (en) 2020-02-27
LT2870160T (lt) 2016-12-12
TW201414740A (zh) 2014-04-16
CR20150045A (es) 2015-05-13
EA033961B1 (ru) 2019-12-13
US20160130300A1 (en) 2016-05-12
PH12020550552A1 (en) 2021-07-26
ES2716138T3 (es) 2019-06-10
ES2605383T3 (es) 2017-03-14
US10335409B2 (en) 2019-07-02
KR20150034698A (ko) 2015-04-03
PL3159345T3 (pl) 2019-09-30
MX360597B (es) 2018-11-09
MD20180040A2 (ro) 2018-11-30
CA2877005C (en) 2016-12-13
EP3159345A1 (en) 2017-04-26
CL2014003634A1 (es) 2015-11-06
EP2870160A1 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
IN2015DN01119A (ar)
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
MX2016006336A (es) Compuestos pirazolopirimidina.
IN2014CN04530A (ar)
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2014MN02652A (ar)
IN2014MN02657A (ar)
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
NZ703162A (en) Heterocyclic modulators of lipid synthesis
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
GB201209587D0 (en) Therapeutic compounds
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors